Parabilis Medicines Inc.
PBLS | NASDAQ
$27.76
-$0.56 (-1.98%)
Nov 2, 2026, 10:36 AM ET · Market open
TTM Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 |
|---|---|---|---|---|
Net Income | -97.78M | -80.13M | -73.14M | -38.33M |
Depreciation & Amortization | 1.2M | 1.22M | 1.27M | 654K |
Stock-Based Compensation | 4.94M | 2.13M | 1.68M | 852K |
Other Working Capital | 32.65M | -4.6M | -2.92M | -2.64M |
Other Non-Cash Items | 8.83M | 4.29M | 4.35M | 1.8M |
Deferred Income Tax | n/a | n/a | n/a | n/a |
Change in Working Capital | 29.99M | -7.81M | 596K | 871K |
Operating Cash Flow | -52.82M | -80.29M | -65.24M | -34.15M |
Capital Expenditures | -985K | -385K | -90K | -74K |
Cash Acquisitions | n/a | n/a | n/a | n/a |
Purchase of Investments | -33.45M | n/a | -16.66M | -16.66M |
Sales Maturities Of Investments | n/a | 24.53M | 47.95M | 23.43M |
Other Investing Acitivies | n/a | n/a | n/a | n/a |
Investing Cash Flow | -34.43M | 24.14M | 31.2M | 6.69M |
Debt Repayment | -7.81M | -4.05M | -284K | -140K |
Common Stock Repurchased | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a |
Other Financial Acitivies | 47.46M | 50M | n/a | n/a |
Financial Cash Flow | 1.15B | 350.76M | 67.15M | 67.29M |
Net Cash Flow | 1.06B | 294.61M | 33.11M | 39.82M |
Free Cash Flow | -53.81M | -80.67M | -65.33M | -34.23M |
Adj. Free Cash Flow | -58.75M | -82.8M | -67.01M | -35.08M |
Maintenance CapEx | -1.05M | n/a | n/a | n/a |
Growth CapEx | -23K | n/a | n/a | n/a |
Owner Earnings | -119.12M | n/a | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove PBLS